rna
interfer
rnai
rapidli
adopt
discoveri
valid
gene
function
cell
cultur
anim
model
studi
use
sequencespecif
small
interf
rna
sirna
sirna
intermedi
oligo
found
bind
rna
induc
silenc
complex
risc
select
degrad
complementari
singlestrand
target
rna
sequencespecif
manner
sirna
use
character
gene
function
high
throughput
screen
potenti
therapeut
target
grow
success
research
tool
also
stir
tremend
interest
use
sirna
therapeut
agent
mani
report
vivo
applic
sirna
inhibitor
success
sever
earli
phase
clinic
trial
broad
therapeut
applic
rnai
therapeut
come
one
major
hurdl
realiz
rnai
therapeut
potenti
overcom
obstacl
sirna
deliveri
local
system
diseas
tissu
review
address
challeng
problem
vivo
sirna
deliveri
potenti
therapeut
applic
potent
specif
inhibitor
gene
express
sirna
rapidli
adopt
prefer
tool
function
genom
research
sirna
oligo
typic
use
inhibit
individu
gene
though
target
multipl
gene
group
gene
possibl
use
combin
multipl
sirna
sequenc
success
use
sirna
knockdown
gene
express
vitro
led
grow
interest
applic
sirna
inhibitor
vivo
evalu
therapeut
potenti
gene
target
interest
potenc
sirna
inhibitor
rout
administr
unwant
advers
effect
applic
eventu
provid
valid
target
convent
therapeut
modal
small
molecul
monoclon
antibodi
inhibitor
well
valid
sirna
drug
lead
fig
one
exampl
use
sirna
oligo
specif
target
angiogenesi
factor
vegf
egf
fgf
receptor
repres
wide
recogn
target
took
year
valid
one
studi
use
sirnamedi
downregul
proangiogenesi
gene
vegf
vegf
clinic
relev
xenograft
tumor
model
result
signific
antitumor
efficaci
thu
function
two
target
valid
rapidli
matter
week
exampl
demonstr
power
vivo
target
valid
sirna
inhibitor
case
role
proangiogen
factor
valid
sirna
inhibitor
also
valid
potenti
anticanc
drug
deliv
sirna
oligo
vivo
anim
tissu
keep
activ
target
cell
complic
involv
use
physic
chemic
biolog
approach
case
combin
sinc
main
goal
vivo
deliveri
activ
sirna
oligo
target
cell
stabil
sirna
oligo
extracellular
intracellular
environ
system
administr
challeng
issu
fig
first
hurdl
size
doublestrand
sirna
oligo
rel
small
thu
rapidli
excret
urin
administr
blood
stream
even
sirna
molecul
remain
stabl
chemic
modif
second
doublestrand
sirna
oligo
rel
unstabl
serum
environ
potenti
degrad
rnase
activ
within
short
period
time
third
sirna
administ
system
nonspecif
distribut
oligo
throughout
bodi
significantli
decreas
local
concentr
site
diseas
addit
sirna
oligo
need
overcom
blood
vessel
endotheli
wall
multipl
tissu
barrier
order
reach
target
cell
final
sirna
reach
target
cell
cellular
uptak
oligo
intracellular
rnai
activ
requir
effici
endocytosi
intact
doublestrand
oligo
increas
stabil
extracellular
intracellular
environ
sirna
oligo
chemic
modifi
varieti
method
includ
chang
oligo
backbon
replac
individu
nucleotid
nucleotid
analogu
ad
conjug
oligo
chemic
modifi
sirna
demonstr
signific
serum
resist
higher
stabil
solv
problem
excret
urin
target
deliveri
therefor
deliveri
system
capabl
protect
sirna
oligo
urinari
excret
rnase
degrad
transport
sirna
oligo
physic
barrier
target
tissu
enhanc
cellular
uptak
sirna
key
success
vivo
sirna
applic
access
differ
tissu
type
presenc
variou
deliveri
rout
varieti
pharmacolog
requir
make
imposs
univers
vivo
deliveri
system
suitabl
everi
scenario
sirna
deliveri
term
vivo
deliveri
vehicl
sirna
nonvir
carrier
major
type
investig
far
though
physic
viral
deliveri
approach
also
effect
rout
vivo
deliveri
commonli
categor
local
system
deliveri
vehicl
deliveri
rout
effect
anim
target
valid
may
use
deliveri
sirna
therapeut
human
fig
therefor
vivo
sirna
deliveri
carrier
method
also
classifi
clinic
viabl
nonclin
viabl
accord
suitabl
human
use
mani
nonvir
carrier
current
use
deliveri
either
sirna
oligo
dnabas
short
hairpin
rna
shrna
vector
rnai
mechan
action
cytoplasm
achiev
effect
sirna
deliveri
rel
easier
achiev
deliveri
dnabas
shrna
system
nonvir
sirna
deliveri
diseas
tissu
usual
elicit
immun
respons
rel
less
toxic
target
cell
great
advantag
drug
target
valid
possibl
multipl
administr
sirna
make
therapeut
applic
sirna
practic
cation
lipid
polym
two
major
class
nonvir
sirna
deliveri
carrier
posit
charg
form
complex
neg
charg
sirna
sirnacarri
complex
condens
tini
nanoparticl
size
around
nm
allow
effici
cellular
uptak
sirna
agent
endocytosi
process
mous
model
report
gene
silenc
downregul
express
achiev
intraperiton
administr
sirnalipoplex
one
recent
studi
report
use
cation
deriv
cardiolipin
form
lipoplex
sirna
target
craf
oncogen
led
inhibit
tumor
growth
sequencespecif
manner
anoth
studi
famili
highli
branch
histidinelysin
hk
polym
peptid
found
effect
carrier
sirna
express
xenograft
significantli
inhibit
intratumor
inject
sirna
complex
hk
polym
fig
anoth
recent
studi
demonstr
signific
inhibit
express
tumor
growth
intraperiton
inject
sirna
formul
polyethylenimin
pei
studi
demonstr
cation
lipid
polym
enhanc
sirna
deliveri
vivo
system
rout
either
intraven
iv
intraperiton
ip
carrieradminist
sirna
agent
effici
knock
target
gene
achiev
antitumor
efficaci
contrast
direct
intratumor
inject
vegf
sirna
without
carrier
gener
signific
antitumor
efficaci
antivir
studi
iv
administr
sirna
specif
target
influenza
viru
rna
genom
complex
pei
abl
inhibit
influenza
viru
product
mice
ligandtarget
nucleic
acid
deliveri
system
develop
base
cation
liposom
complex
polym
complex
system
recent
success
use
ligandtarget
complex
deliv
therapeut
sirna
tumor
tissu
liver
tissu
suggest
target
system
deliveri
sirna
therapeut
possibl
demonstr
effici
deliveri
sirna
local
neovasculatur
tumor
xenograft
viral
infect
eye
system
administr
ligandtarget
nanoparticl
contain
sirna
target
vegf
angiogenesi
factor
overexpress
endothelium
new
blood
vessel
argglyasp
rgd
motif
peptid
ligand
specif
integrin
receptor
marker
activ
endotheli
tumor
cell
ligandtarget
nanoparticl
maintain
stabil
sirna
payload
target
tumor
neovasculatur
enhanc
cellular
uptak
sirna
result
vegf
knockdown
antiangiogenesi
effect
observ
xenograft
tumor
model
ocular
neovascular
diseas
model
clearli
sirna
nanoparticl
clinic
viabl
deliveri
system
variou
applic
sirna
therapeut
report
sirna
trigger
offtarget
effect
activ
cellular
interferon
pathway
issu
rais
concern
integr
target
valid
studi
safeti
select
potenti
sirna
therapeut
howev
major
alarm
result
found
vitro
studi
mani
studi
shown
sirna
inhibitor
highli
specif
vitro
vivo
one
recent
studi
use
system
deliveri
unmodifi
unformul
sirna
oligo
mice
reveal
lack
interferon
respons
two
recent
report
reveal
sirna
oligo
contain
motif
abl
induc
tolllik
receptormedi
interferon
respons
deliv
vivo
cation
lipid
polym
carrier
either
intraven
intraperiton
administr
contrast
neither
unformul
sirna
oligo
contain
motif
sirna
contain
motif
cation
carrier
abl
induc
interferon
respons
reason
motif
potenti
immunostimulatori
motif
elimin
sirna
oligo
cation
lipid
polym
carrier
go
use
airway
deliveri
sirna
use
method
target
valid
therapeut
develop
relev
respiratori
system
variou
diseas
recent
studi
intranas
deliveri
gapdhspecif
sirna
mix
pulmonari
surfac
activ
materi
infasurf
elastas
result
lower
gapdh
protein
level
lung
heart
kidney
day
administr
compar
scrambl
sirna
control
direct
deliveri
unformul
sirna
mous
airway
led
knockdown
heme
express
lung
intranas
administr
cation
liposom
formul
sirna
specif
target
influenza
viru
rna
genom
mous
lung
infect
influenza
viru
result
significantli
reduc
lung
viru
titer
infect
mice
protect
anim
lethal
challeng
howev
vivo
deliveri
sirna
cation
polym
carrier
pei
often
associ
sever
toxic
host
may
induc
nonspecif
interferon
respons
tolllik
receptor
pathway
discuss
earlier
therefor
pulmonari
sirna
deliveri
may
requir
formul
without
cation
carrier
late
success
deliv
sirna
dglucos
water
solut
mous
monkey
lung
achiev
effect
knockdown
sar
coronaviru
rna
fig
increas
number
clinic
protocol
approv
treat
eye
diseas
nucleic
acid
drug
antisens
oligonucleotid
rna
aptam
deliveri
nonformul
sirna
specif
vegf
subretin
space
mous
model
retin
neovascular
result
signific
reduct
angiogenesi
eye
importantli
studi
indic
chemic
protect
sirna
essenti
least
intravitr
compart
eye
contrast
antisens
oligonucleotid
rna
aptam
need
protect
chemic
modif
applic
eye
use
murin
model
herpet
stromal
ketat
develop
herp
simplex
viru
corneal
infect
found
subconjunctiv
administr
sirna
target
sever
gene
vegf
pathway
significantli
inhibit
corneal
angiogenesi
diseas
symptom
subconjunctiv
deliveri
sirna
specif
significantli
reduc
inflammatori
respons
matrix
deposit
woundinduc
mous
model
ocular
inflamm
evid
also
provid
clinic
viabl
mean
local
deliveri
sirna
gene
function
valid
variou
eye
diseas
model
local
deliveri
sirna
front
eye
subconjunctiv
back
eye
intravitr
highli
effici
silenc
target
gene
express
therefor
effect
administr
rout
target
valid
eye
diseas
howev
frequenc
time
interv
repeat
deliveri
may
limit
factor
deliveri
rout
especi
clinic
applic
sirna
therapeut
brain
tissu
foundat
central
nervou
system
cn
obvious
import
biolog
system
one
repres
consider
interest
function
genom
research
therapeut
develop
recent
studi
show
infus
chemic
protect
sirna
oligonucleotid
aqueou
solut
directli
brain
abl
select
inhibit
gene
express
treatment
rat
aqueou
sirna
ar
day
birth
result
acut
decreas
level
ar
mrna
brainstem
sirna
inject
nonvir
infus
sirna
brain
provid
uniqu
approach
acceler
target
valid
neuropsychiatr
disord
involv
complex
interplay
gene
variou
brain
region
exampl
infus
sirna
specif
endogen
dopamin
transport
dat
gene
region
ventral
midbrain
far
distal
infus
site
result
signific
downregul
dat
mrna
protein
brain
elicit
tempor
hyperlocomotor
respons
similar
obtain
upon
infus
pharmacolog
select
dat
inhibitor
howev
difficulti
perform
surgic
implant
infus
pump
deliv
high
dose
sirna
limit
use
tool
function
genom
anoth
recent
studi
use
cation
formul
sirna
deliveri
brain
reveal
deliveri
effici
use
lipid
carrier
use
polym
carrier
electropor
physic
approach
use
introduc
dna
cell
process
electropor
electr
field
puls
induc
pore
electropor
cell
membran
allow
dna
molecul
enter
cell
recent
electropor
procedur
adopt
local
deliveri
sirna
one
studi
sirna
introduc
hippocampu
region
local
electropor
led
mark
reduct
express
mrna
protein
target
gene
without
affect
express
protein
skeletalmuscl
tissu
access
local
sirna
administr
direct
inject
sirna
formul
cation
lipid
polym
consid
local
deliveri
although
inflamm
caus
inject
common
problem
recent
studi
nonformul
sirna
deliv
direct
inject
mous
muscl
follow
electropor
demonstr
signific
gene
silenc
last
day
electropor
method
also
appli
differ
studi
target
sever
report
gene
murin
skelet
muscl
local
hydrodynam
approach
sirna
suffici
volum
rapidli
inject
distal
vein
limb
transient
isol
tourniquet
blood
pressur
cuff
test
sirna
deliveri
muscl
anim
model
demonstr
knockdown
report
endogen
gene
intratumor
deliveri
sirna
attract
approach
function
valid
tumorigen
gene
observ
inhibit
tumor
growth
two
human
breast
cancer
xenograft
model
use
intratumor
deliveri
vegfspecif
sirna
report
atelocollagen
collagen
solubil
proteas
protect
sirna
digest
rnase
form
complex
sirna
addit
sirna
slowli
releas
atelocollagen
effici
transduc
cell
allow
longterm
target
gene
silenc
mous
xenograft
tumor
studi
administr
atelocollagenlucsirna
complex
intratumor
reduc
luciferas
express
observ
furthermor
intratumor
inject
atelocollagenvegfsirna
show
effici
inhibit
tumor
growth
orthotop
xenograft
model
human
nonseminomat
germ
cell
tumor
similar
result
observ
human
prostat
xenograft
tumor
model
use
sirna
deliveri
approach
therefor
atelocollagenbas
sirna
deliveri
method
could
reliabl
approach
achiev
maxim
inhibit
gene
function
vivo
basi
experi
success
valid
group
novel
gene
role
tumorgenesi
use
intratumor
deliveri
formul
sirna
believ
intratumor
deliveri
sirna
xenograft
tumor
model
use
platform
vivo
target
valid
first
publish
result
show
activ
sirna
mammal
deliv
mous
liver
use
hydrodynam
deliveri
rapid
inject
larg
volum
aqueou
solut
mous
tail
vein
creat
high
pressur
vascular
circul
lead
extens
deliveri
sirna
hepatocyt
procedur
allow
high
effici
sirna
uptak
potent
sirna
activ
hepatocyt
thu
use
tool
function
genom
studi
liver
hand
procedur
clinic
viabl
procedur
potenti
damag
liver
organ
limit
research
liver
function
metabol
liver
infecti
diseas
hepat
hepatocytespecif
target
carrier
sirna
deliveri
liver
attract
approach
develop
sirna
therapeut
hepat
diseas
current
investig
one
step
toward
liver
target
deliveri
liver
deliveri
chemic
modifi
oligonucleotid
cholesterol
conjug
test
describ
recent
public
howev
data
suggest
least
three
challeng
must
address
adequ
protect
sirna
oligonucleotid
serum
degrad
en
rout
liver
protect
sirna
oligonucleotid
rapid
glomerulofiltr
kidney
urin
select
uptak
target
hepatocyt
addit
high
dose
use
intraven
cholesterolconjug
sirna
deliveri
indic
widespread
distribut
rather
target
liver
malign
tumor
grow
fast
spread
throughout
bodi
via
blood
lymphat
system
metastat
tumor
establish
distant
locat
usual
encapsul
thu
amen
system
deliveri
local
sirna
administr
method
discuss
earlier
meet
requir
function
genom
studi
act
primari
tumor
xenograft
model
form
basi
cancer
biolog
research
hand
system
deliveri
sirna
need
develop
sirnabas
cancer
therapeut
system
sirna
deliveri
impos
sever
requir
greater
hurdl
local
sirna
deliveri
requir
stabl
oligonucleotid
blood
local
environ
enter
target
cell
addit
sirna
need
pass
multipl
tissu
barrier
reach
target
cell
recent
studi
pancrea
xenograft
use
system
administr
sirna
without
protect
formul
studi
demonstr
signific
suppress
primari
tumor
growth
compar
control
sirna
associ
decreas
prolifer
index
tumor
cell
impair
angiogenesi
increas
apoptosi
treatment
sirna
complet
inhibit
metastasi
significantli
improv
surviv
without
appar
toxic
recent
result
reveal
tumortarget
sirna
deliveri
use
rgd
peptid
ligand
direct
nanoparticl
applic
antiangiogen
treatment
cancer
fig
system
sirna
deliveri
review
elsewher
recent
addit
target
tumor
neovasculatur
also
studi
rgd
ligand
target
nanoparticl
target
ocular
neovasculatur
tissu
antiangiogenesi
efficaci
observ
ocular
neovascular
model
demonstr
approach
clinic
viabl
method
sirna
therapeut
fig
use
hsv
dna
induc
ocular
neovascular
model
demonstr
sirna
oligo
specif
sever
gene
combin
nanoparticl
cocktail
approach
achiev
stronger
antiangiogenesi
activ
inhibit
diseas
patholog
liganddirect
nanoparticl
deliveri
repres
novel
effect
approach
clinic
viabl
system
administr
sirna
oligo
dualtarget
rnai
therapeut
current
deliveri
sirna
oligo
therapeut
agent
vivo
either
local
system
rout
evolv
target
valid
tool
proof
principl
potenti
rnai
therapeut
therefor
examin
util
particular
sirna
deliveri
method
vivo
requir
confirm
robust
target
valid
process
repeat
test
preclin
model
one
signific
advantag
sirna
howev
rapid
differ
sirna
sequenc
match
gene
studi
particularli
use
drug
target
valid
moreov
develop
optim
sirna
deliveri
variou
type
anim
diseas
model
challeng
worthi
effort
acceler
novel
drug
discoveri
process
ultim
effort
translat
clinic
viabl
administr
method
sirnabas
therapeut
treat
cancer
infecti
diseas
mani
critic
diseas
